166 related articles for article (PubMed ID: 19897764)
1. Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.
Vezina HE; Balfour HH; Weller DR; Anderson BJ; Brundage RC
J Clin Pharmacol; 2010 Jul; 50(7):734-42. PubMed ID: 19897764
[TBL] [Abstract][Full Text] [Related]
2. A virologic pilot study of valacyclovir in infectious mononucleosis.
Balfour HH; Hokanson KM; Schacherer RM; Fietzer CM; Schmeling DO; Holman CJ; Vezina HE; Brundage RC
J Clin Virol; 2007 May; 39(1):16-21. PubMed ID: 17369082
[TBL] [Abstract][Full Text] [Related]
3. Antiviral agents for infectious mononucleosis (glandular fever).
De Paor M; O'Brien K; Fahey T; Smith SM
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011487. PubMed ID: 27933614
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
Lerner AM; Beqaj SH; Deeter RG; Fitzgerald JT
In Vivo; 2007; 21(5):707-13. PubMed ID: 18019402
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.
Olson D; Gulley ML; Tang W; Wokocha C; Mechanic O; Hosseinipour M; Gold SH; Nguluwe N; Mwansambo C; Shores C
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):112-8. PubMed ID: 23260601
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy.
Kimberlin DF; Weller S; Whitley RJ; Andrews WW; Hauth JC; Lakeman F; Miller G
Am J Obstet Gynecol; 1998 Oct; 179(4):846-51. PubMed ID: 9790357
[TBL] [Abstract][Full Text] [Related]
8. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.
Smiley ML; Murray A; de Miranda P
Adv Exp Med Biol; 1996; 394():33-9. PubMed ID: 8815698
[No Abstract] [Full Text] [Related]
9. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.
Hoshino Y; Katano H; Zou P; Hohman P; Marques A; Tyring SK; Follmann D; Cohen JI
J Virol; 2009 Nov; 83(22):11857-61. PubMed ID: 19740997
[TBL] [Abstract][Full Text] [Related]
10. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients.
Ozçay F; Arslan H; Bilezikçi B; Sevmiş S; Moray G; Haberal M
Transplant Proc; 2009 Sep; 41(7):2878-80. PubMed ID: 19765462
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir.
Walling DM; Flaitz CM; Nichols CM
J Infect Dis; 2003 Sep; 188(6):883-90. PubMed ID: 12964120
[TBL] [Abstract][Full Text] [Related]
12. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity.
Höllsberg P; Kusk M; Bech E; Hansen HJ; Jakobsen J; Haahr S
Acta Neurol Scand; 2005 Dec; 112(6):395-402. PubMed ID: 16281923
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.
Kimberlin DW; Jacobs RF; Weller S; van der Walt JS; Heitman CK; Man CY; Bradley JS
Clin Infect Dis; 2010 Jan; 50(2):221-8. PubMed ID: 20014952
[TBL] [Abstract][Full Text] [Related]
14. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
[TBL] [Abstract][Full Text] [Related]
16. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.
Lerner AM; Beqaj SH; Deeter RG; Dworkin HJ; Zervos M; Chang CH; Fitzgerald JT; Goldstein J; O'Neill W
Drugs Today (Barc); 2002 Aug; 38(8):549-61. PubMed ID: 12582420
[TBL] [Abstract][Full Text] [Related]
17. Extrapolation of Valacyclovir Posology to Children Based on Pharmacokinetic Modeling.
Kechagia IA; Kalantzi L; Dokoumetzidis A
Pediatr Infect Dis J; 2015 Dec; 34(12):1342-8. PubMed ID: 26379165
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir.
Zeng L; Nath CE; Blair EY; Shaw PJ; Stephen K; Earl JW; Coakley JC; McLachlan AJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2918-27. PubMed ID: 19414579
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
20. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
Sabo JP; Cong XJ; Kraft MF; Wallace L; Castles MA; Mauss S; MacGregor TR
Eur J Clin Pharmacol; 2011 Mar; 67(3):277-81. PubMed ID: 20963404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
